nach oben

Diabetologia

Erschienen in:

01.11.2009 | Review

Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications

verfasst von: A. Bierhaus, P. P. Nawroth

Erschienen in: Diabetologia | Ausgabe 11/2009

Einloggen, um Zugang zu erhalten

Abstract

The pattern recognition receptor or receptor for AGE (RAGE) is constitutionally expressed in a few cell types only. However in almost all cells studied so far it is induced by reactions known to initiate inflammation. Its biological activity seems to be mainly dependent on the presence of its various ligands, including AGE, S100-calcium binding protein/calgranulins, high-mobility group protein 1, amyloid-β-peptides and the family of β-sheet fibrils, all known to be elevated in chronic metabolic, malignant and inflammatory diseases. The RAGE pathway interacts with cytokine-, lipopolysaccharide-, oxidised LDL- and glucose-triggered cellular reactions by turning a short-lasting inflammatory response into a sustained change of cellular function driven by perpetuated activation of the proinflammatory transcription factor, nuclear factor kappa-B. RAGE-mediated persistent cell activation is of pivotal importance in various experimental and clinical settings, including diabetes and its complications, neurodegeneration, ageing, tumour growth, and autoimmune and infectious inflammatory disease. Due to RAGE’s central role in maintaining perpetuated cell activation, various therapeutic attempts to block RAGE or its ligands are currently under investigation. Despite broad experimental evidence for the role of RAGE in chronic disease, knowledge of its physiological function is still missing, limiting predictions about safety of long-term inhibition of RAGE × ligand interaction in chronic diseases.

Hudson BI, Stickland MH, Grant PJ, Futers TS (2001) Characterization of allelic and nucleotide variation between the RAGE gene on chromosome 6 and a homologous pseudogene sequence to its 5′ regulatory region on chromosome 3: implications for polymorphic studies in diabetes. Diabetes 50:2646–2651PubMedCrossRef

Schmidt AM, Yan SD, Yan SF, Stern DM (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108:949–955PubMed

Neeper M, Schmidt AM, Brett J et al (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267:14998–15004PubMed

Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D (1994) Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 14:1521–1528PubMed

Yan SD, Stern D, Schmidt AM (1997) What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose. Eur J Clin Invest 27:179–181PubMedCrossRef

Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP (1998) AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 37:586–600PubMedCrossRef

Thornalley PJ (1998) Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol (Noisy-le-grand) 44:1013–1023

Bierhaus A, Humpert PM, Morcos M et al (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83:876–886PubMedCrossRef

Bierhaus A, Schiekofer S, Schwaninger M et al (2001) Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50:2792–2808PubMedCrossRef

10.

Constien R, Forde A, Liliensiek B et al (2001) Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis 30:36–44PubMedCrossRef

11.

Bierhaus A, Haslbeck KM, Humpert PM et al (2004) Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest 114:1741–1751PubMed

12.

Liliensiek B, Weigand MA, Bierhaus A et al (2004) Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 113:1641–1650PubMed

13.

Sparvero LJ, Asafu-Adjei D, Kang R et al (2009) RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 7:17PubMedCrossRef

14.

Gebhardt C, Riehl A, Durchdewald M et al (2008) RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 205:275–285PubMedCrossRef

15.

Yan SF, Ramasamy R, Schmidt AM (2009) Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med 87:235–247PubMedCrossRef

16.

Yan SF, Du Yan S, Ramasamy R, Schmidt AM (2009) Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann Med: 1–15

17.

Coughlan MT, Thorburn DR, Penfold SA et al (2009) RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 20:742–752PubMedCrossRef

18.

Li JH, Wang W, Huang XR et al (2004) Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Pathol 164:1389–1397PubMed

19.

Dattilo BM, Fritz G, Leclerc E, Kooi CW, Heizmann CW, Chazin WJ (2007) The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. Biochemistry 46:6957–6970PubMedCrossRef

20.

Osawa M, Yamamoto Y, Munesue S et al (2007) De-N-glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced glycation endproducts. Biochim Biophys Acta 1770:1468–1474PubMed

21.

Srikrishna G, Huttunen HJ, Johansson L et al (2002) N-Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth. J Neurochem 80:998–1008PubMedCrossRef

22.

Turovskaya O, Foell D, Sinha P et al (2008) RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 29:2035–2043PubMedCrossRef

23.

Kalea AZ, Reiniger N, Yang H, Arriero M, Schmidt AM, Hudson BI (2009) Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J 23:1766–1774PubMedCrossRef

24.

Foell D, Wittkowski H, Roth J (2007) Mechanisms of disease: a ‘DAMP’ view of inflammatory arthritis. Nat Clin Pract Rheumatol 3:382–390PubMedCrossRef

25.

Kalousova M, Zima T, Tesar V, Dusilova-Sulkova S, Skrha J (2005) Advanced glycoxidation end products in chronic diseases—clinical chemistry and genetic background. Mutat Res 579:37–46PubMed

26.

Marsche G, Semlitsch M, Hammer A et al (2007) Hypochlorite-modified albumin colocalizes with RAGE in the artery wall and promotes MCP-1 expression via the RAGE-Erk1/2 MAP-kinase pathway. Faseb J 21:1145–1152PubMedCrossRef

27.

Anderstam B, Ann-Christin BH, Valli A, Stenvinkel P, Lindholm B, Suliman ME (2008) Modification of the oxidative stress biomarker AOPP assay: application in uremic samples. Clin Chim Acta 393:114–118PubMedCrossRef

28.

Capeillere-Blandin C, Gausson V, Descamps-Latscha B, Witko-Sarsat V (2004) Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochim Biophys Acta 1689:91–102PubMed

29.

Witko-Sarsat V, Friedlander M, Capeillere-Blandin C et al (1996) Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49:1304–1313PubMedCrossRef

30.

Ahmed N, Thornalley PJ (2002) Chromatographic assay of glycation adducts in human serum albumin glycated in vitro by derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and intrinsic fluorescence. Biochem J 364:15–24PubMed

31.

Hofmann MA, Drury S, Fu C et al (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97:889–901PubMedCrossRef

32.

Leclerc E, Fritz G, Vetter SW, Heizmann CW (2009) Binding of S100 proteins to RAGE: an update. Biochim Biophys Acta 1793:993–1007PubMedCrossRef

33.

Deane R, Du Yan S, Submamaryan RK et al (2003) RAGE mediates amyloid-beta peptide transport across the blood–brain barrier and accumulation in brain. Nat Med 9:907–913PubMedCrossRef

34.

Huttunen HJ, Fages C, Rauvala H (1999) Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 274:19919–19924PubMedCrossRef

35.

Chavakis T, Bierhaus A, Al-Fakhri N et al (2003) The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 198:1507–1515PubMedCrossRef

36.

Jandeleit-Dahm K, Cooper ME (2008) The role of AGEs in cardiovascular disease. Curr Pharm Des 14:979–986PubMedCrossRef

37.

Bouma G, Lam-Tse WK, Wierenga-Wolf AF, Drexhage HA, Versnel MA (2004) Increased serum levels of MRP-8/14 in type 1 diabetes induce an increased expression of CD11b and an enhanced adhesion of circulating monocytes to fibronectin. Diabetes 53:1979–1986PubMedCrossRef

38.

Kosaki A, Hasegawa T, Kimura T et al (2004) Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. J Clin Endocrinol Metab 89:5423–5428PubMedCrossRef

39.

Yan XX, Lu L, Peng WH et al (2008) Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis. doi:10.1016/j.atherosclerosis.2008.12.016

40.

Soro-Paavonen A, Watson AM, Li J et al (2008) Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 57:2461–2469PubMedCrossRef

41.

Liu Y, Liu H, Yang J et al (2008) Increased amyloid beta-peptide (1–40) level in brain of streptozotocin-induced diabetic rats. Neuroscience 153:796–802PubMedCrossRef

42.

Andrassy M, Igwe J, Autschbach F et al (2006) Posttranslationally modified proteins as mediators of sustained intestinal inflammation. Am J Pathol 169:1223–1237PubMedCrossRef

43.

Buetler TM, Leclerc E, Baumeyer A et al (2008) N(epsilon)-carboxymethyllysine-modified proteins are unable to bind to RAGE and activate an inflammatory response. Mol Nutr Food Res 52:370–378PubMedCrossRef

44.

Kislinger T, Fu C, Huber B et al (1999) N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274:31740–31749PubMedCrossRef

45.

Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW (1999) The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 104:103–113PubMedCrossRef

46.

Bierhaus A, Stern DM, Nawroth PP (2006) RAGE in inflammation: a new therapeutic target? Curr Opin Investig Drugs 7:985–991PubMed

47.

Ehlermann P, Eggers K, Bierhaus A et al (2006) Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol 5:6PubMedCrossRef

48.

Pullerits R, Brisslert M, Jonsson IM, Tarkowski A (2006) Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1. Arthritis Rheum 54:3898–3907PubMedCrossRef

49.

Raucci A, Cugusi S, Antonelli A et al (2008) A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). Faseb J 22:3716–3727PubMedCrossRef

50.

Zhang L, Bukulin M, Kojro E et al (2008) Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem 283:35507–35516PubMedCrossRef

51.

Cheng C, Tsuneyama K, Kominami R et al (2005) Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol 18:1385–1396PubMedCrossRef

52.

Hudson BI, Carter AM, Harja E et al (2008) Identification, classification, and expression of RAGE gene splice variants. Faseb J 22:1572–1580PubMedCrossRef

53.

Santilli F, Vazzana N, Bucciarelli LG, Davi G (2009) Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem 16:940–952PubMedCrossRef

54.

Nakamura K, Yamagishi S, Adachi H et al (2008) Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc Res 76:52–56PubMedCrossRef

55.

Nin JW, Ferreira I, Schalkwijk CG et al (2009) Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia 52:705–714PubMedCrossRef

56.

Humpert PM, Djuric Z, Kopf S et al (2007) Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 6:9PubMedCrossRef

57.

Forbes JM, Thorpe SR, Thallas-Bonke V et al (2005) Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 16:2363–2372PubMedCrossRef

58.

Nakamura K, Yamagishi S, Nakamura Y et al (2005) Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res 70:137–141PubMedCrossRef

59.

Santilli F, Bucciarelli L, Noto D et al (2007) Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med 43:1255–1262PubMedCrossRef

60.

Tan KC, Chow WS, Tso AW et al (2007) Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. Diabetologia 50:1819–1825PubMedCrossRef

61.

Donato R, Sorci G, Riuzzi F et al (2008) S100B's double life: intracellular regulator and extracellular signal. Biochim Biophys Acta 1793:1008–1022PubMed

62.

Hudson BI, Kalea AZ, Del Mar Arriero M et al (2008) Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem 283:34457–34468PubMedCrossRef

63.

Lin L, Park S, Lakatta EG (2009) RAGE signaling in inflammation and arterial aging. Front Biosci 14:1403–1413PubMedCrossRef

64.

Abeyama K, Stern DM, Ito Y et al (2005) The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 115:1267–1274PubMed

65.

Isermann B, Vinnikov IA, Madhusudhan T et al (2007) Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 13:1349–1358PubMedCrossRef

66.

Orlova VV, Choi EY, Xie C et al (2007) A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. Embo J 26:1129–1139PubMedCrossRef

67.

Bierhaus A, Chevion S, Chevion M et al (1997) Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 46:1481–1490PubMedCrossRef

68.

Thornalley PJ (2003) Glyoxalase I—structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans 31:1343–1348PubMedCrossRef

69.

Vander Jagt DL (2008) Methylglyoxal, diabetes mellitus and diabetic complications. Drug Metabol Drug Interact 23:93–124PubMed

70.

Morcos M, Du X, Pfisterer F et al (2008) Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans. Aging Cell 7:260–269PubMedCrossRef

71.

Humpert PM, Lukic IK, Thorpe SR et al (2009) AGE-modified albumin containing infusion solutions boosts septicaemia and inflammation in experimental peritonitis. J Leukoc Biol. doi:10.1189/jlb.1008646 PubMed

72.

Kokkola R, Andersson A, Mullins G et al (2005) RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 61:1–9PubMedCrossRef

73.

Chavakis T, Bierhaus A, Nawroth PP (2004) RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect 6:1219–1225PubMedCrossRef

74.

Tian J, Avalos AM, Mao SY et al (2007) Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 8:487–496PubMedCrossRef

75.

Yan SS, Wu ZY, Zhang HP et al (2003) Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med 9:287–293PubMedCrossRef

76.

Su X, Lee JW, Matthay ZA et al (2007) Activation of the alpha7 nAChR reduces acid-induced acute lung injury in mice and rats. Am J Respir Cell Mol Biol 37:186–192PubMedCrossRef

77.

Ohgami N, Nagai R, Ikemoto M et al (2002) CD36, serves as a receptor for advanced glycation endproducts (AGE). J Diabetes Complications 16:56–59PubMedCrossRef

78.

van Zoelen MA, Marieke AD, Yang H, et al. (2009) Role of Toll-like receptors 2 and 4, and the receptor for advanced glycation end products (RAGE) in HMGB1 induced inflammation in vivo. Shock 31:280–284

79.

Manfredi AA, Capobianco A, Esposito A et al (2008) Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes. J Immunol 180:2270–2275PubMed

80.

Chen Y, Akirav EM, Chen W et al (2008) RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol 181:4272–4278PubMed

81.

Dumitriu IE, Baruah P, Valentinis B et al (2005) Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 174:7506–7515PubMed

82.

Moser B, Desai DD, Downie MP et al (2007) Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo. J Immunol 179:8051–8058PubMed

83.

Ritthaler U, Deng Y, Zhang Y et al (1995) Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol 146:688–694PubMed

84.

Bucciarelli LG, Wendt T, Qu W et al (2002) RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106:2827–2835PubMedCrossRef

85.

Wendt T, Harja E, Bucciarelli L et al (2006) RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 185:70–77PubMedCrossRef

86.

Park L, Raman KG, Lee KJ et al (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4:1025–1031PubMedCrossRef

87.

Nawroth P, Bierhaus A, Marrero M, Yamamoto H, Stern DM (2005) Atherosclerosis and restenosis: is there a role for RAGE? Curr Diab Rep 5:11–16PubMedCrossRef

88.

Sakaguchi T, Yan SF, Yan SD et al (2003) Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 111:959–972PubMed

89.

Fujii H, Li SH, Szmitko PE, Fedak PW, Verma S (2006) C-reactive protein alters antioxidant defenses and promotes apoptosis in endothelial progenitor cells. Arterioscler Thromb Vasc Biol 26:2476–2482PubMedCrossRef

90.

Chen J, Huang L, Song M, Yu S, Gao P, Jing J (2009) C-reactive protein upregulates receptor for advanced glycation end products expression and alters antioxidant defenses in rat endothelial progenitor cells. J Cardiovasc Pharmacol 53:359–367PubMedCrossRef

91.

Yan SD, Bierhaus A, Nawroth PP, Stern DM (2009) Endothelial precursor cells and CRP on the RAGE: activation or cell death? J Cardiovasc Pharmacol 53:349–351PubMedCrossRef

92.

Limana F, Germani A, Zacheo A et al (2005) Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circ Res 97:e73–e83PubMedCrossRef

93.

Kohno T, Anzai T, Naito K et al (2009) Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. Cardiovasc Res 81:565–573PubMedCrossRef

94.

Andrassy M, Volz HC, Igwe JC et al (2008) High-mobility group box-1 in ischemia–reperfusion injury of the heart. Circulation 117:3216–3226PubMedCrossRef

95.

Andrassy M, Volz CH, Bianchi ME, Kaya Z, Bierhaus A, Katus HA (2008) The role of Hmgb1 in the development of diabetic cardiomyopathy. Circulation 118:S351–S352

96.

Muhammad S, Barakat W, Stoyanov S et al (2008) The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci 28:12023–12031PubMedCrossRef

97.

Yamamoto Y, Kato I, Doi T et al (2001) Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108:261–268PubMed

98.

Wendt TM, Tanji N, Guo J et al (2003) RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162:1123–1137PubMed

99.

Tan AL, Forbes JM, Cooper ME (2007) AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 27:130–143PubMedCrossRef

100.

Toth C, Rong LL, Yang C et al (2008) Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes 57:1002–1017PubMedCrossRef

101.

Wang Y, Vom Hagen F, Pfister F et al (2008) Receptor for advanced glycation end product expression in experimental diabetic retinopathy. Ann N Y Acad Sci 1126:42–45PubMedCrossRef

102.

Barile GR, Schmidt AM (2007) RAGE and its ligands in retinal disease. Curr Mol Med 7:758–765PubMedCrossRef

103.

Hammes HP, Du X, Edelstein D et al (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9:294–299PubMedCrossRef

104.

Hammes HP, Hoerauf H, Alt A et al (1999) N(epsilon)(carboxymethyl)lysin and the AGE receptor RAGE colocalize in age-related macular degeneration. Invest Ophthalmol Vis Sci 40:1855–1859PubMed

105.

Gaens KH, van Der Kallen CJ, van Greevenbroek MM, Feskens EJ, Stehouwer CD, Schalkwijk CG (2008) Receptor for advanced glycation end product polymorphisms and type 2 diabetes: the CODAM study. Ann N Y Acad Sci 1126:162–165PubMedCrossRef

106.

Prevost G, Fajardy I, Besmond C et al (2005) Polymorphisms of the receptor of advanced glycation endproducts (RAGE) and the development of nephropathy in type 1 diabetic patients. Diabetes Metab 31:35–39PubMedCrossRef

107.

Rudofsky G Jr, Isermann B, Schilling T et al (2004) A 63 bp deletion in the promoter of rage correlates with a decreased risk for nephropathy in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 112:135–141PubMedCrossRef

108.

Kankova K, Sebekova K (2005) Genetic variability in the RAGE gene: possible implications for nutrigenetics, nutrigenomics, and understanding the susceptibility to diabetic complications. Mol Nutr Food Res 49:700–709PubMedCrossRef

Titel: Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications
verfasst von: A. Bierhaus
P. P. Nawroth
Publikationsdatum: 01.11.2009
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 11/2009
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-009-1458-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Update Innere Medizin

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2009

Central nervous insulin resistance: a promising target in the treatment of metabolic and cognitive disorders?

Intensive glucose control and macrovascular outcomes in type 2 diabetes

Interferon regulatory factor-1 is a key transcription factor in murine beta cells under immune attack

Endothelial cell signalling supports pancreatic beta cell function in the rat

Contact frequency determines outcome of basal insulin initiation trials in type 2 diabetes

Reduced endoplasmic reticulum (ER)-to-Golgi protein trafficking contributes to ER stress in lipotoxic mouse beta cells by promoting protein overload

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Update Innere Medizin